Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 812 results for "bristol myers squibb"

Market Update: Bristol-Myers Squibb Company (NYSE:BMY)  Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27
Jutia Group

Market Update: Bristol-Myers Squibb Company (NYSE:BMY) Bristo...

at 10:00 AM EST [Business Wire] Bristol-Myers Squibb Company will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015. During a conference call at 9 a.m. EST on J . . . → Read More: Market Update: ... Wall Street Select, 21 hours ago
[x]  

115 images for bristol myers squibb

Jutia Group, 19 hours ago
Bidness Etc, 1 week ago
Bidness Etc, 1 week ago
Jutia Group, 2 weeks ago
Jutia Group, 2 weeks ago
Philanthropy News Digest, 1 month ago
Irish Times, 1 month ago
Silicon Republic, 1 month ago
Irish Times, 1 month ago
Jutia Group, 3 weeks ago

Bristol-Myers reports January 27

News Editor Bristol-Myers Squibb (BMY +0.9%) will report Q4 and full-year results on January 27 before the open. The conference call will begin at 9:00 am ET. Consensus views for Q4 and 2014 are EPS of $0.41 and $1.80 on revenues of $4.0B and ...
 Seeking Alpha21 hours ago

Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Endo Intl., and Allergan

has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), and Allergan Inc. (NYSE: AGN). Free ...
 Pettinga Financial Advisors23 hours ago Allergan : Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Endo Intl., and Allergan  4 Traders23 hours ago
[x]  

Bristol Myers (BMY) Showing Bullish Technicals With Support At $56.95

For a hedged play on Bristol-Myers Squibb Co (http://www.marketintelligencecenter.com/symbol/BMY"BMY) MarketIntelligenceCenter.comaEUR(TM)s algorithms selected the Mar. '15 $57.50 covered call for a net debit in the $55.10 area. That is also the ...
 Individual.com1 day ago Bristol Myers (BMY) Trading Near $60.36 Resistance Level  Individual.com2 days ago Bristol Myers (BMY) Showing Bearish Technicals With Resistance At $59.38  Individual.com22 hours ago Bristol Myers (BMY) Trading Near $59.80 Resistance Level  Individual.com1 week ago

Ono Pharma, Bristol-Myers Squibb, Kyowa Hakko Kirin Collaborate On Immuno-Oncology Drug Study

By Suzanne Hodsden , contributing writer Three companies are combining their efforts on a new immuno-oncology drug study that will test the efficacy of using Opdivo and mogamulizumab together to treat advanced or metastatic solid tumors. Ono ...
 Bioresearch Online2 days ago Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo nivolumab and...  4 Traders8 hours ago Ono Pharma, Bristol-Myers & Kyowa Hakko Kirin enter pact to condutct phase 1 combo study with Opdivo & mogamulizumab in advanced solid tumors  4 Traders23 hours ago Bristol-Myers sets up collaborative cancer study in Japan  Seeking Alpha1 week ago
[x]  

Bristol-Myers Squibb Receives Average Recommendation of Hold from Brokerages (NYSE:BMY)

Shares of Bristol-Myers Squibb (NYSE:BMY) have earned a consensus recommendation of "Hold" from the nineteen ratings firms that are presently covering the stock, Stock Ratings News reports. One equities research analyst has rated the stock with a ...
 American Banking News1 day ago Morningstar Assigns AA- Credit Rating to Bristol-Myers Squibb (BMY)  WKRB News3 days ago Bristol-Myers Squibb Shares Up 15.2% Since SmarTrend's Buy Recommendation (BMY)  Individual.com1 week ago Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for...  Pharmacy Choice1 week ago
[x]  

Potential Bristol Myers (BMY) Trade Has 6.58% Downside Protection

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center Aare highlighting two trades on Bristol-Myers Squibb Co (http://www.marketintelligencecenter.com/symbol/BMY"BMY) today after it ...
 Individual.com6 days ago

SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 1.56% Loss

(Comtex SmarTrend(R)) Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.74 to a high of $59.95. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $59.12 on volume of 6.5 ...
 Individual.com5 days ago

Bristol Myers Squibb declares $0.37 dividend

Bristol-Myers Squibb (NYSE:BMY) declares $0.37/share quarterly dividend, 2.8% increase from prior dividend of $0.36. Forward yield 2.47% Payable Feb. 2; for shareholders of record Jan 2; ex-div
 Seeking Alpha1 week ago Bristol-Myers Squibb Co (BMY) Announces Quarterly Dividend of $0.37  American Banking News1 week ago Bristol-Myers Squibb Co. (BMY) Pops 2.99% for December 05  Equities.com1 week ago

Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data

Bristol-Myers Squibb Company ( BMY ) announced encouraging data from the ongoing phase Ib CheckMate - 039 study on immuno-oncology drug Opdivo (nivolumab, a PD-1 immune checkpoint inhibitor). Data from the study was published in The New England ...
 Yahoo! Finance1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less